Evidence map›Paper›PMID 40458489›Full record

ArticleAnnals of internal medicine. Clinical cases2024

Use of Maribavir for Multidrug-Resistant Cytomegalovirus in an Immunocompromised Host With HIV and Common Variable Immunodeficiency.

Diana Zarowin, Jared Coe, Maxwell Bressman, Paul Riska, Philip Yune, Ghaleb Halaseh, Matthew J Akiyama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of internal medicine. Clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Diana ZarowinAlbert Einstein College of Medicine, Bronx, New York.
Jared CoeDepartment of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York.
Maxwell BressmanDepartment of Medicine, Division of General Internal Medicine, Montefiore Medical Center, Bronx, New York.
Paul RiskaDepartment of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York.
Philip YuneDepartment of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York.
Ghaleb HalasehDepartment of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York.
Matthew J AkiyamaAlbert Einstein College of Medicine, Bronx, New York.

Funding

Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject DrugsDP2DA053730 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2021 to 2021
$2.5M
NIDA NIH HHS DP2 DA053730
6 · The paper itself

Abstract

We present a case of multidrug-resistant Cytomegalovirus (CMV) and the use of maribavir, a novel oral treatment of resistant CMV, in a nontransplant immunocompromised host. Our patient initially was diagnosed with CMV pharyngitis on biopsy. Although his initial CMV pharyngitis resolved, the CMV isolated from blood became resistant to ganciclovir and cidofovir and eventually required treatment with foscarnet. Our patient was given a trial of maribavir. After 6 weeks, the patient's viremia resolved and remained undetectable for 6 months after treatment initiation with maribavir. This case demonstrates the feasibility of using maribavir for resistant CMV in a nontransplant, immunocompromised patient.

Indexed as

Cytomegalovirus infectionHematopoietic stem cell transplantationHIVImmunodeficienciesImmunosuppressionMultidrug resistanceMutationPharyngitisProphylaxisSystemic diseaseTransplantationViral loadViremia

Identifiers

PMID40458489
PMCPMC12129374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.